. In a previously published series of 1010 gliomas 71 % of the tumors carried an IDH1 mutation. Of these 93% were characterized by a base-pair exchange of guanine to adenine (G395A), leading to the substitution of the amino acid arginine by histidine (R132H) 2 . In acute myeloid leukemia (AML), mutations of either IDH1 or isocitrate dehydrogenase 2 (IDH2) were detected in up to 50% of the tumors [3] [4] [5] [6] . In contrast to diffuse glioma, IDH1R132C mutations appear to be more frequent than IDH1R132H and very recent data suggest that IDH2 mutations may represent the most frequent mutations in these tumors 3, 5 . Sequencing analyses suggested that IDH1 mutations are rare in other tumors [7] [8] . The current clinical importance for knowledge on IDH1 mutations in glioma is based on the observation in clinical trials and prospective studies: IDH1 mutation is associated with a significant better prognosis [9] [10] .
Biochemical studies revealed that mutant IDH1 protein looses its ability to convert isocitrate to α-ketoglutarate [11] [12] .
Another potentially 2HG-independent mechanism of tumor promotion by IDH1 mutations has been proposed: mutant IDH1 results in a lack of α-ketoglutarate (α-KG) which is necessary for maintaining the activity of prolylhydroxylases. Active prolylhydroxylases in turn promote the degradation of HIF-1α.
IDH1 mutation mediated reduction of prolylhydroxylases thus results in an increased HIF-1α activity known for its tumor promoting effects 17 .
Therefore, analysis of tumor specimens for mutated IDH1 protein, especially the most common variant IDH1 R132H , is important for both clinicians and researchers. The development of a mutation specific antibody suitable also for immunohistochemistry (IHC) on formalin-fixed paraffin-embedded (FFPE)
tissue allows efficient screening of large tumor collections for the R132H mutation [18] [19] . IHC allows diagnostic routine analysis and has the advantage of being rapidly performed and allows detection of IDH1 R132H protein in its morphological setting. In this study, we investigated 1844 tumors for presence of IDH1 R132H by IHC. 
Material and Methods
Tissue specimens 
Immunohistochemistry
For immunohistochemstry we used the previously described antibody against mutant IDH1 R132H protein, clone H09 (Dianova, Hamburg, Germany) [18] [19] . Sections cut to 3µm were incubated and processed with clone H09 on a Ventana BenchMark XT® immunostainer (Ventana Medical Systems, Tucson, AZ, USA). The Ventana staining procedure included pretreatment with cell conditioner 2 (pH 6) for 60min, followed by incubation H09 hybridoma supernatant at 37°C for 32min.
Incubation was followed by Ventana standard signal amplification, UltraWash, counterstaining with one drop of hematoxylin for 4min and one drop of bluing reagent for 4min. For visualization, ultraView™Universal DAB Detection Kit (Ventana Medical Systems) was used. Binding of antibody was scored as previously described 19 .
PCR amplification and direct sequencing
DNA was extracted from FFPE tissue of 7 cases with ambiguous binding pattern using standard protocols. A fragment spanning the catalytic domain of IDH1 including codon 132 was amplified using 60ng each of the primer IDH1f TGATGAGAAGAGGGTTGAGGA and the primer IDH1r ATCCCCATAAGCATGACGAC. Primer design was based on accession number NM_005896. For PCR, 20ng of DNA and 2x PCR Master Mix (Promega, Madison, WI, USA) were employed. PCR was performed in a total volume of 15µl, and included initial denaturation at 180°C for 30s, followed by 35 cycles with denaturation at 95°C for 30s, annealing at 56°C for 40s and extension at 72°C for 50s.
Two microliters of the amplification product was submitted to sequencing using the BigDye® [7] [8] . A very recent study detected 3 IDH1 mutations in 38 thyroid cancers, however the mutations detected did not affect codon 132 of
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. We did not find either IDH1R132H mutation in the 4 thyroid carcinomas from our series.
Data on IDH1 status in sarcoma was not available so far. Our study contains 364 different sarcomas, including angiosarcoma, leiomyosarcoma, synovial sarcoma, liposarcoma, myxofibrosarcoma and malignant fibrous histiocytoma. IHC for IDH1 R132H protein did not reveal any mutation in sarcomas.
All together, our data confirm on protein level the absence or extreme rarity of IDH1R132H mutations in epithelial and sarcomatous tumors.
Acute myeloid leukemia (AML) so far is the only non CNS tumor described with a substantial number of IDH1 mutations. We, therefore, extended our series to include additional hematopoietic neoplasms. 
